BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Jayne D, Rovin B, Mysler EF, Furie RA, Houssiau FA, Trasieva T, Knagenhjelm J, Schwetje E, Chia YL, Tummala R, Lindholm C. Phase II randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritis. Ann Rheum Dis 2022:annrheumdis-2021-221478. [PMID: 35144924 DOI: 10.1136/annrheumdis-2021-221478] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 22.0] [Reference Citation Analysis]
Number Citing Articles
1 Jalal A, Li T. The evolving landscape of immune-mediated glomerular diseases. Nat Rev Nephrol 2023;19:81-2. [PMID: 36517620 DOI: 10.1038/s41581-022-00666-w] [Reference Citation Analysis]
2 Nawata A, Nakayamada S, Hisano S, Miyazaki Y, Miyamoto T, Shiba E, Hisaoka M, Tanaka Y. Differential renal expression of IFN-α and BAFF and its relevance to disease activity and treatment responsiveness in patients with proliferative lupus nephritis.. [DOI: 10.21203/rs.3.rs-2480720/v1] [Reference Citation Analysis]
3 Bruera S, Chavula T, Madan R, Agarwal SK. Targeting type I interferons in systemic lupus erythematous. Front Pharmacol 2023;13. [DOI: 10.3389/fphar.2022.1046687] [Reference Citation Analysis]
4 Anders HJ, Kitching AR, Leung N, Romagnani P. Glomerulonephritis: immunopathogenesis and immunotherapy. Nat Rev Immunol 2023;:1-19. [PMID: 36635359 DOI: 10.1038/s41577-022-00816-y] [Reference Citation Analysis]
5 Felten R, Scherlinger M, Mertz P, Chasset F, Arnaud L. New biologics and targeted therapies in systemic lupus: From new molecular targets to new indications. A systematic review. Joint Bone Spine 2023;90:105523. [PMID: 36623799 DOI: 10.1016/j.jbspin.2023.105523] [Reference Citation Analysis]
6 Lee YH, Song GG. Comparative Efficacy and Safety of Biological Agents in the Treatment of Lupus Nephritis: A Network Meta-Analysis. Pharmacology 2023;108:17-26. [PMID: 36327917 DOI: 10.1159/000527223] [Reference Citation Analysis]
7 Lazaro E. Quoi de neuf en médecine interne ? Annales de Dermatologie et de Vénéréologie - FMC 2022;2:2/8S80-2/8S83. [DOI: 10.1016/s2667-0623(22)01091-1] [Reference Citation Analysis]
8 Lichtnekert J, Anders H, Lech M. Lupus Nephritis: Current Perspectives and Moving Forward. JIR 2022;Volume 15:6533-6552. [DOI: 10.2147/jir.s363722] [Reference Citation Analysis]
9 Mcadoo SP, Pusey CD. ANCA-Associated Vasculitis, Anti-GBM Disease, and Lupus Nephritis. nephsap 2022;21:364-382. [DOI: 10.1681/nsap.00122022] [Reference Citation Analysis]
10 Kwant LE, Vegting Y, Tsang-A-Sjoe MWP, Kwakernaak AJ, Vogt L, Voskuyl AE, van Vollenhoven RF, de Winther MPJ, Bemelman FJ, Anders HJ, Hilhorst ML. Macrophages in Lupus Nephritis: Exploring a potential new therapeutic avenue. Autoimmun Rev 2022;21:103211. [PMID: 36252930 DOI: 10.1016/j.autrev.2022.103211] [Reference Citation Analysis]
11 Ceccarelli F, Govoni M, Piga M, Cassone G, Cantatore FP, Olivieri G, Cauli A, Favalli EG, Atzeni F, Gremese E, Iannone F, Caporali R, Sebastiani M, Ferraccioli GF, Lapadula G, Conti F. Arthritis in Systemic Lupus Erythematosus: From 2022 International GISEA/OEG Symposium. JCM 2022;11:6016. [DOI: 10.3390/jcm11206016] [Reference Citation Analysis]
12 Liu Z, Cheng R, Liu Y. Evaluation of anifrolumab safety in systemic lupus erythematosus: A meta-analysis and systematic review. Front Immunol 2022;13:996662. [DOI: 10.3389/fimmu.2022.996662] [Reference Citation Analysis]
13 Córdoba-david G, García-giménez J, Cardoso Castelo-branco R, Carrasco S, Cannata P, Ortiz A, Ramos AM. Crosstalk between TBK1/IKKε and the type I interferon pathway contributes to tubulointerstitial inflammation and kidney tubular injury. Front Pharmacol 2022;13. [DOI: 10.3389/fphar.2022.987979] [Reference Citation Analysis]
14 Steiger S, Ehreiser L, Anders J, Anders H. Biological drugs for systemic lupus erythematosus or active lupus nephritis and rates of infectious complications. Evidence from large clinical trials. Front Immunol 2022;13:999704. [DOI: 10.3389/fimmu.2022.999704] [Reference Citation Analysis]
15 Moysidou G, T. Boumpas D. Targeted Therapies for Systemic Lupus Erythematosus (SLE): A Critical Appraisal. Systemic Lupus Erythematosus - Pathogenesis and Management [Working Title] 2022. [DOI: 10.5772/intechopen.105811] [Reference Citation Analysis]
16 Nasonov EL, Soloviev SK, Arshinov AV. Systemic lupus erythematosus: history and modernity. Naučno-praktičeskaâ revmatologiâ 2022;60:397-412. [DOI: 10.47360/1995-4484-2022-397-412] [Reference Citation Analysis]
17 Weeding E, Fava A, Mohan C, Magder L, Goldman D, Petri M. Urine proteomic insights from the belimumab in lupus nephritis trial. Lupus Sci Med 2022;9:e000763. [PMID: 36167482 DOI: 10.1136/lupus-2022-000763] [Reference Citation Analysis]
18 Kirou KA, Dall`era M, Aranow C, Anders H. Belimumab or anifrolumab for systemic lupus erythematosus? A risk-benefit assessment. Front Immunol 2022;13:980079. [DOI: 10.3389/fimmu.2022.980079] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
19 Parodis I, Gatto M, Sjöwall C. B cells in systemic lupus erythematosus: Targets of new therapies and surveillance tools. Front Med 2022;9. [DOI: 10.3389/fmed.2022.952304] [Reference Citation Analysis]
20 Moroni G, Calatroni M, Ponticelli C. Severe lupus nephritis in the present days. Front Nephrol 2022;2. [DOI: 10.3389/fneph.2022.984613] [Reference Citation Analysis]
21 Yu C, Li P, Dang X, Zhang X, Mao Y, Chen X. Lupus nephritis: new progress in diagnosis and treatment. J Autoimmun 2022;:102871. [PMID: 35999111 DOI: 10.1016/j.jaut.2022.102871] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
22 Russell LA, Craig C, Flores EK, Wainaina JN, Keshock M, Kasten MJ, Hepner DL, Edwards AF, Urman RD, Mauck KF, Oprea AD. Preoperative Management of Medications for Rheumatologic and HIV Diseases: Society for Perioperative Assessment and Quality Improvement (SPAQI) Consensus Statement. Mayo Clin Proc 2022;97:1551-71. [PMID: 35933139 DOI: 10.1016/j.mayocp.2022.05.002] [Reference Citation Analysis]
23 Uresti-Rivera EE, García-Hernández MH. AIM2-inflammasome role in systemic lupus erythematous and rheumatoid arthritis. Autoimmunity 2022;:1-12. [PMID: 35880661 DOI: 10.1080/08916934.2022.2103802] [Reference Citation Analysis]
24 Alenzi F, P. D’cruz D. Recent Advances in SLE Treatment Including Biologic Therapies. Systemic Lupus Erythematosus - Pathogenesis and Management [Working Title] 2022. [DOI: 10.5772/intechopen.105558] [Reference Citation Analysis]
25 Plüß M, Piantoni S, Wincup C, Korsten P. Rapid Response of Refractory Systemic Lupus Erythematosus Skin Manifestations to Anifrolumab-A Case-Based Review of Clinical Trial Data Suggesting a Domain-Based Therapeutic Approach. J Clin Med 2022;11:3449. [PMID: 35743519 DOI: 10.3390/jcm11123449] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
26 Brady MP, Chava S, Tandon S, Rane MJ, Barati MT, Caster DJ, Powell DW. Serum and Urine Interferon Gamma-Induced Protein 10 (IP-10) Levels in Lupus Nephritis. J Clin Med 2022;11:3199. [PMID: 35683585 DOI: 10.3390/jcm11113199] [Reference Citation Analysis]
27 Plüß M, Piantoni S, Tampe B, Kim AHJ, Korsten P. Belimumab for systemic lupus erythematosus - Focus on lupus nephritis. Hum Vaccin Immunother 2022;:2072143. [PMID: 35588699 DOI: 10.1080/21645515.2022.2072143] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
28 Steiger S, Anders HJ. Interferon blockade in lupus: effects on antiviral immunity. Nat Rev Nephrol 2022. [PMID: 35523957 DOI: 10.1038/s41581-022-00581-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
29 Sim TM, Ong SJ, Mak A, Tay SH. Type I Interferons in Systemic Lupus Erythematosus: A Journey from Bench to Bedside. Int J Mol Sci 2022;23:2505. [PMID: 35269647 DOI: 10.3390/ijms23052505] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
30 Ganguly D. Therapeutic Targeting of Plasmacytoid Dendritic Cells. Plasmacytoid Dendritic Cells 2022. [DOI: 10.1007/978-981-19-5595-2_9] [Reference Citation Analysis]
31 Mishra D, Samanta J. Future of digital health and precision medicine in rheumatology practice in India. Indian J Rheumatol 2022;17:426. [DOI: 10.4103/injr.injr_146_22] [Reference Citation Analysis]